Organogenesis (NASDAQ:ORGO) Trading 9.1% Higher on Analyst Upgrade

Organogenesis Holdings Inc. (NASDAQ:ORGO) shares rose 9.1% during trading on Wednesday after Morgan Stanley raised their price target on the stock from $4.00 to $6.00. Morgan Stanley currently has an equal weight rating on the stock. Organogenesis traded as high as $5.65 and last traded at $5.50. Approximately 322,446 shares traded hands during mid-day trading, a decline of 69% from the average daily volume of 1,055,605 shares. The stock had previously closed at $5.04.

Insider Buying and Selling at Organogenesis

In other Organogenesis news, CEO Gary S. Gillheeney sold 41,052 shares of the company’s stock in a transaction that occurred on Monday, December 9th. The stock was sold at an average price of $3.52, for a total transaction of $144,503.04. Following the completion of the transaction, the chief executive officer now owns 3,359,726 shares of the company’s stock, valued at $11,826,235.52. This represents a 1.21 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Insiders have sold 278,116 shares of company stock valued at $991,190 in the last 90 days. 36.90% of the stock is currently owned by company insiders.

Institutional Trading of Organogenesis

A number of institutional investors have recently made changes to their positions in the business. Wealth Enhancement Advisory Services LLC bought a new position in Organogenesis in the third quarter valued at $96,000. Metis Global Partners LLC bought a new position in shares of Organogenesis in the 3rd quarter valued at about $84,000. Connor Clark & Lunn Investment Management Ltd. increased its position in shares of Organogenesis by 5.6% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 471,240 shares of the company’s stock valued at $1,348,000 after acquiring an additional 24,878 shares during the last quarter. Intech Investment Management LLC acquired a new stake in shares of Organogenesis in the third quarter valued at about $43,000. Finally, Charles Schwab Investment Management Inc. raised its holdings in Organogenesis by 2.6% during the third quarter. Charles Schwab Investment Management Inc. now owns 948,451 shares of the company’s stock worth $2,713,000 after acquiring an additional 23,675 shares in the last quarter. Institutional investors own 49.57% of the company’s stock.

Organogenesis Stock Up 19.2 %

The company has a debt-to-equity ratio of 0.21, a current ratio of 3.09 and a quick ratio of 2.74. The firm has a 50-day moving average of $3.56 and a 200 day moving average of $3.31. The stock has a market capitalization of $762.24 million, a price-to-earnings ratio of -100.17 and a beta of 1.66.

About Organogenesis

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.